<DOC>
	<DOCNO>NCT01785056</DOCNO>
	<brief_summary>The purpose research study effect Privigen ( intravenous immunoglobulin ) skin patient scleroderma . Approximately 24 subject take part investigator-initiated study Georgetown University Hospital Johns Hopkins Hospital . This study last one year ( 12 month ) . This research do systemic sclerosis cause severe , progressive organ involvement . The investigator hope study treatment improve outcome disease , include skin , muscle , joint , gastrointestinal , lung involvement .</brief_summary>
	<brief_title>IVIG Treatment Systemic Sclerosis</brief_title>
	<detailed_description>The investigator propose double-blind control trial 24 patient Privigen® ( Immune Globulin Intravenous ( Human ) , 10 % liquid treatment ) 3:1 randomization . Subjects scleroderma give 2 g/kg/mo Privigen® placebo ( Albuminar®-5 ) 6 month . Scleroderma generally progressive disease , skin improve time patient , others progressive disease spite aggressive treatment . Also , spontaneous improvement organ system even less likely . Patients enter trial fail respond standard care treatment past 4 month . Thus , investigator feel actual improvement observe attributed IVIG treatment . Since pilot study , future large control trial necessary clearly demonstrate effectiveness , investigator hop study give u signal guide future clinical trial .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Diffuse systemic sclerosis active skin involvement define mRSS &gt; 12 , improvement worsen previous 4 month spite treatment methotrexate , cellcept , imuran , antiTNF agent ; 18 year age old ; Disease duration le 5 year first nonRaynaud 's symptom scleroderma . Use 10 mg prednisone , dose cytoxan , dpenicillamine , rituximab last 3 month ; History deep vein thrombosis ( DVT ) , stroke , thromboembolic phenomenon ; History anaphylaxis serious reaction human blood blood product . Absolute IgA deficiency A prior receipt IVIg treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Systemic Sclerosis</keyword>
	<keyword>Diffuse Scleroderma</keyword>
	<keyword>SSc</keyword>
</DOC>